In addition, a study base on patients with chronic obstructive pulmonary disease (COPD) also observed that Fluvastatin and Atorvastatin are more effective in reducing C-reactive protein and pulmonary hypertension (Lu et al., 2019). This evidence concerns the gene CRP and pulmonary arterial hypertension.